CA ‐125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high‐grade ovarian cancer

ConclusionsReduction of CA ‐125 levels during neoadjuvant chemotherapy provides an early predictive tool that strongly correlates with successful cytoreductive surgery and long‐term clinical outcome in patients with advanced high grade serous and endometrioid ovarian cancer.

Source: Acta Obstetricia et Gynecologica Scandinavica - January 17, 2020 Category: OBGYN Authors: Roy Kessous, Michel D. Wissing, Sabrina Piedimonte, Jeremie Abitbol, Liron Kogan, Ido Laskov, Amber Yasmeen, Shannon Salvador, Susie Lau, Walter H. Gotlieb Tags: ORIGINAL RESEARCH ARTICLE Source Type: research